Peptides›GH secretagogue›CJC-1295 with DAC

CJC-1295 with DAC

/ Modified human GHRH(1-29) analog with drug-affinity-complex (DAC) maleimide group for covalent albumin binding

SPECULATIVEN = 0 · TESTING PENDINGMW 4544.00 g·mol⁻¹

ALIAS · CJC-1295 DAC · Long-acting GHRH analog · CJC-1295(DAC) · GHRH(1-29)-DAC

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (with DAC linker)

MW · 4544.00CLASS · Modified human GHRH(1-29) analog with drug-affinity-complex (DAC) maleimide group for covalent albumin bindingCATEGORY · GH secretagogue

Tier 4 in current literature. The original Phase 1 work (Teichman 2006) showed pharmacokinetic proof-of-concept for a once-weekly long-acting GHRH analog via covalent albumin binding (DAC technology). No Phase 2 or Phase 3 development continued; not approved anywhere.

§ B · Mechanism of action

CJC-1295 is a modified GHRH(1-29) analog with a maleimidopropionyl linker (the 'DAC' — drug affinity complex) that forms a covalent bond with serum albumin in vivo. Albumin binding extends the half-life from minutes (native GHRH) to roughly one to two weeks, producing sustained GHRH receptor stimulation at the somatotrope and elevated mean GH and IGF-1 levels.

§ C · Human clinical evidence

Tier 4. A single 2006 Phase 1 single-ascending-dose study in healthy adults demonstrated dose-dependent IGF-1 elevation lasting up to 28 days post-injection. No Phase 2 or Phase 3 trials of CJC-1295 with DAC have been published.

§ D · Primary literature

PubMed16352683Teichman SL et al. — Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · The Journal of Clinical Endocrinology & Metabolism · human-phase-1Single-dose CJC-1295 produced dose-dependent GH and IGF-1 elevation lasting up to 28 days; established the DAC pharmacokinetic mechanism.Limitations: Phase 1 only; sponsor (ConjuChem) authors; no published follow-up Phase 2 or 3 trials.2006

PubMed17018654Ionescu M et al. — Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog · Journal of Clinical Endocrinology & Metabolism · human-phase-1Despite sustained GHRH receptor stimulation by CJC-1295, endogenous GH secretion remained pulsatile, indicating preserved somatostatin-driven negative feedback at the somatotrope.Limitations: Small Phase 1 cohort; short-duration assessment; same investigator group as the original Teichman 2006 paper.2006

§ F · Safety signal

Phase 1 reported injection site reactions and transient flushing; small sample size and short follow-up cap the safety database. Sustained GH/IGF-1 elevation over months has not been characterised in humans.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Marketed by research-chemical vendors with claims of weekly dosing, but the published human PK data come from one Phase 1 study by the molecule's developers (ConjuChem). Independent replication, long-term outcomes, and Phase 2/3 efficacy data do not exist. Vendor product purity and identity vary.